Polymeric Nanoplatforms for Immunotherapy and Diagnosis
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 174
Special Issue Editors
Interests: cancer therapy; immunotherapy; immunodiagnosis; biomedical polymer; disease diagnosis
Interests: cancer therapy; immunotherapy; drug delivery systems
Special Issues, Collections and Topics in MDPI journals
Interests: polymeric drug and protein delivery systems in cancers; inflammatory diseases; bacteria-related diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy targeting the host immune system has revolutionized oncology. However, due to uncontrolled accumulation in tissues and the ever-present bioactivity of immunotherapeutics, most patients suffer from the risk of immune-related adverse events (IRAEs). With the advantages of controllability of delivery and modular flexibility, polymeric nanoplatforms offer the opportunity to bring immunotherapies into clinical use in a safe and effective manner. In addition, patients with many non-immunogenic “cold” tumors show low response rates to immunotherapies, especially checkpoint blockade therapies, so in addition to polymeric nanoplatforms for immunotherapies, real-time tracking of the immune microenvironment of tumors is essential for the efficacy of immunotherapies.
To promote the development in the field of immunotherapy, the introduction of new polymeric nanoplatforms for immunotherapy and diagnosis is of great significance. The proposed topics will primarily focus on the demonstration of novel polymeric materials and provide a general picture of the suitability of a particular material for immunotherapy and diagnosis.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Immunotherapy;
- Cancer immunotherapy;
- Polymeric nanoplatforms;
- Diagnosis;
- Drug delivery systems;
- Biomaterials;
- Immunodiagnosis.
We look forward to receiving your contributions.
Prof. Dr. Shasha He
Prof. Dr. Jingchao Li
Prof. Dr. Dongfang Zhou
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- cancer immunotherapy
- polymeric nanoplatforms
- diagnosis
- drug delivery systems
- biomaterials
- immunodiagnosis
